Katz SI, Roshkovan L, Berger I, et al. - Given that soluble mesothelin-related protein (SMRP) and fibulin-3 serum concentrations may have utility as diagnostic as well as prognostic biomarkers of malignant pleural mesothelioma (MPM), so researchers evaluated these markers for their association with tumor volume, prognosis as well as response evaluation in a clinical trial of immunogene therapy in combination with chemotherapy. Among adult patients with biopsy-confirmed MPM who were enrolled in two prospective clinical trials, serial serum concentrations of SMRP and fibulin-3 were assessed. Experts calculated pre-therapy computed tomography (CT) measurements of tumor burden and correlated these with pre-therapy serum SMRP and fibulin-3 levels in these two trials. Findings showed that SMRP and fibulin-3 had correlations with initial tumor volumes as assessed by CT scanning, but no benefit for following tumor response longitudinally was conferred by SMRP and fibulin-3 when used as serological biomarkers in the immunotherapy trial.